Daniel E Speiser Selected Research

Antibodies

5/2022	Increased Receptor Affinity and Reduced Recognition by Specific Antibodies Contribute to Immune Escape of SARS-CoV-2 Variant Omicron.
1/2020	Minimal immune response to booster vaccination against Yellow Fever associated with pre-existing antibodies.
1/2019	Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients.
11/2018	T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.
9/2017	Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma.
12/2014	Pulmonary sarcoid-like granulomatosis after multiple vaccinations of a long-term surviving patient with metastatic melanoma.
10/2002	Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel E Speiser Research Topics

Disease

130	Neoplasms (Cancer) 04/2024 - 01/2002
78	Melanoma (Melanoma, Malignant) 03/2024 - 01/2002
10	Neoplasm Metastasis (Metastasis) 01/2022 - 05/2004
7	Testicular Neoplasms (Testicular Cancer) 01/2019 - 02/2006
6	Infections 05/2022 - 02/2003
6	Inflammation (Inflammations) 01/2022 - 01/2015
6	Communicable Diseases (Infectious Diseases) 01/2021 - 06/2005
5	Virus Diseases (Viral Diseases) 01/2021 - 01/2010
4	Persistent Infection 10/2023 - 06/2013
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 01/2016
4	Colorectal Neoplasms (Colorectal Cancer) 11/2017 - 06/2007
3	Yellow Fever 01/2020 - 04/2015
3	Urinary Bladder Neoplasms (Bladder Cancer) 01/2020 - 02/2017
3	Colonic Neoplasms (Colon Cancer) 12/2015 - 11/2007
3	Human Influenza (Influenza) 08/2010 - 07/2004
2	Carcinoma (Carcinomatosis) 04/2024 - 01/2022
2	Lung Neoplasms (Lung Cancer) 03/2024 - 01/2021
2	Breast Neoplasms (Breast Cancer) 11/2023 - 10/2017
2	Ovarian Neoplasms (Ovarian Cancer) 10/2023 - 11/2018
2	Colitis 01/2019 - 11/2016
2	Non-Muscle Invasive Bladder Neoplasms 08/2017 - 02/2017
2	Multiple Myeloma 01/2014 - 02/2008
2	Squamous Cell Carcinoma of Head and Neck 02/2013 - 06/2011
1	Head and Neck Neoplasms (Head and Neck Cancer) 04/2024
1	Immune System Diseases (Immune Disorders) 01/2023
1	Parkinson Disease (Parkinson's Disease) 01/2023
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2023
1	COVID-19 07/2020
1	Wounds and Injuries (Trauma) 01/2020

Drug/Important Bio-Agent (IBA)

55	Peptides (Polypeptides)IBA 04/2024 - 01/2002
47	AntigensIBA 03/2024 - 02/2002
29	VaccinesIBA 04/2024 - 10/2002
29	MART-1 AntigenIBA 01/2022 - 01/2002
20	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 01/2002
16	CytokinesIBA 10/2023 - 04/2005
14	Proteins (Proteins, Gene)FDA Link 10/2023 - 03/2007
11	LigandsIBA 04/2024 - 01/2010
10	EpitopesIBA 10/2023 - 10/2003
9	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2016
9	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2016
8	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2023 - 09/2008
8	HLA-A*02:01 antigenIBA 09/2014 - 02/2003
7	AntibodiesIBA 05/2022 - 10/2002
6	incomplete Freund's adjuvantIBA 03/2016 - 10/2003
6	HLA-A2 Antigen (HLA A2 Antigen)IBA 01/2014 - 10/2002
5	IpilimumabIBA 10/2020 - 03/2014
5	Cancer VaccinesIBA 01/2019 - 09/2003
4	RNA (Ribonucleic Acid)IBA 11/2023 - 09/2015
4	Interleukin-2 (IL2)IBA 01/2013 - 04/2005
4	AutoantigensIBA 01/2013 - 03/2008
3	NanovaccinesIBA 04/2024 - 01/2019
3	Transcription Factors (Transcription Factor)IBA 10/2023 - 12/2008
3	InterferonsIBA 01/2021 - 10/2020
3	Granzymes (Granzyme)IBA 01/2021 - 03/2007
3	NivolumabIBA 10/2020 - 01/2016
3	Blocking AntibodiesIBA 01/2020 - 01/2012
3	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 01/2013
3	Indicators and Reagents (Reagents)IBA 01/2020 - 08/2010
3	Programmed Cell Death 1 ReceptorIBA 11/2018 - 06/2013
3	human soluble LAG-3 proteinIBA 03/2016 - 01/2011
3	Monoclonal AntibodiesIBA 05/2015 - 04/2005
3	OligodeoxyribonucleotidesIBA 03/2008 - 07/2006
3	Protein Subunit VaccinesIBA 04/2005 - 01/2002
2	Toll-Like Receptors (Toll-Like Receptor)IBA 04/2024 - 01/2019
2	ChromatinIBA 12/2023 - 01/2021
2	Interleukin-13IBA 01/2023 - 08/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 09/2017
2	Neutralizing AntibodiesIBA 01/2021 - 07/2020
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 08/2015
2	Adenosine (Adenocard)FDA LinkGeneric 01/2020 - 10/2019
2	pembrolizumabIBA 07/2019 - 11/2016
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2019 - 10/2009
2	Differentiation AntigensIBA 01/2019 - 02/2006
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2019 - 02/2013
2	Messenger RNA (mRNA)IBA 11/2017 - 06/2011
2	Monatide (IMS 3015)IBA 03/2016 - 11/2012
2	EMD 521873IBA 01/2013 - 01/2013
2	ProMune (CpG 7909)IBA 06/2012 - 03/2005
1	Circular RNAIBA 03/2024
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2023
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 10/2023
1	Interleukin-18 (Interleukin 18)IBA 01/2023
1	Viral AntigensIBA 01/2023
1	Antiviral Agents (Antivirals)IBA 01/2023
1	Peroxynitrous Acid (Peroxynitrite)IBA 10/2022
1	Oxidants (Oxidizing Agents)IBA 10/2022
1	Tetanus ToxinIBA 01/2022
1	CollagenIBA 01/2022
1	Tyrosine (L-Tyrosine)FDA Link 01/2022
1	NucleotidesIBA 10/2020
1	BO-112IBA 10/2020
1	Poly I-CIBA 10/2020
1	Cell Surface ReceptorsIBA 01/2020

Therapy/Procedure

55	Immunotherapy 01/2023 - 01/2002
44	Therapeutics 12/2023 - 04/2005
5	Drug Therapy (Chemotherapy) 04/2014 - 03/2008
3	Injections 01/2022 - 02/2017
2	Transplantation 01/2023 - 01/2016
2	Cell- and Tissue-Based Therapy (Cell Therapy) 10/2020 - 05/2015
1	Lasers (Laser) 11/2023